Junxian Yu

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Meta-analysis and pharmacoeconomic study of rasagiline versus selegiline in the treatment of Parkinson's disease.

Meta-analysis and pharmacoeconomic study of rasagiline versus selegiline in the treatment of Parkinson's disease.

Journal: Annals of medicine

Published: August 19, 2026

Machine learning models predict the immunotherapy response in tumors on the basis of DNA methylation.

Machine learning models predict the immunotherapy response in tumors on the basis of DNA methylation.

Journal: Epigenomics

Published: June 06, 2026

Mature tertiary lymphoid structures tumor microenvironment-based risk model to assess patients with pancreatic ductal adenocarcinoma.

Mature tertiary lymphoid structures tumor microenvironment-based risk model to assess patients with pancreatic ductal adenocarcinoma.

Journal: Translational cancer research

Published: July 22, 2025

Using Machine Learning to Predict the Prognosis of Cervical Cancer Patients with Lymph Node Metastasis: An Analysis Based on the SEER Database.

Using Machine Learning to Predict the Prognosis of Cervical Cancer Patients with Lymph Node Metastasis: An Analysis Based on the SEER Database.

Journal: Reproductive sciences (Thousand Oaks, Calif.)

Published: December 19, 2024

Transformer-Based Model for Drug Design and Therapy Response Prediction.

Transformer-Based Model for Drug Design and Therapy Response Prediction.

Journal: Chemical biology & drug design

Published: October 21, 2024

Research trends and highlights in PD-1/PD-L1 inhibitor immunotherapy in lung cancer: a bibliometric analysis.

Research trends and highlights in PD-1/PD-L1 inhibitor immunotherapy in lung cancer: a bibliometric analysis.

Journal: Discover oncology

Published: September 11, 2024

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with KRAS mutations: A network meta-analysis.

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with KRAS mutations: A network meta-analysis.

Journal: The clinical respiratory journal

Published: October 31, 2023

Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50.

Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50.

Journal: BMC cancer

Published: April 20, 2023

Immune-Related Colitis Induced by Camrelizumab: A Case Report.

Immune-Related Colitis Induced by Camrelizumab: A Case Report.

Journal: Journal of inflammation research

Published: February 03, 2023

Efficacy and adverse events of immune checkpoint inhibitors in esophageal cancer patients: Challenges and perspectives for immunotherapy.

Efficacy and adverse events of immune checkpoint inhibitors in esophageal cancer patients: Challenges and perspectives for immunotherapy.

Journal: Asia-Pacific journal of clinical oncology

Published: October 24, 2022

The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials.

The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials.

Journal: Disease markers

Published: May 30, 2022

Immune checkpoint inhibitor-related pneumonitis induced by camrelizumab: a case report and review of literature.

Immune checkpoint inhibitor-related pneumonitis induced by camrelizumab: a case report and review of literature.

Journal: Annals of palliative medicine

Published: January 05, 2021

Showing 1-12 of 26

Last Updated: 09/26/2026